Novo Nordisk A/S, Eli Lilly and Company, GE HealthCare Technologies, Sarepta Therapeutics, Thermo Fisher Scientific, Merck & Co., Inc., and AstraZeneca are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture and market medicinal drugs and therapies. Their performance is driven by factors such as clinical-trial outcomes, regulatory approvals, patent lifecycles and competitive pressures in the healthcare market. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
NVO traded down $3.89 on Wednesday, hitting $50.05. 47,847,247 shares of the company's stock traded hands, compared to its average volume of 10,151,013. The company's 50 day simple moving average is $70.43 and its 200-day simple moving average is $73.37. Novo Nordisk A/S has a one year low of $50.02 and a one year high of $139.74. The firm has a market cap of $223.49 billion, a price-to-earnings ratio of 14.83, a P/E/G ratio of 1.33 and a beta of 0.64. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70.
Read Our Latest Research Report on NVO
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE:LLY traded up $3.43 during trading on Wednesday, hitting $766.38. The company had a trading volume of 2,259,646 shares, compared to its average volume of 3,771,983. The stock has a market cap of $726.33 billion, a price-to-earnings ratio of 62.21, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The company has a fifty day simple moving average of $773.36 and a two-hundred day simple moving average of $800.41. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53.
Read Our Latest Research Report on LLY
GE HealthCare Technologies (GEHC)
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.
NASDAQ:GEHC traded down $4.64 during midday trading on Wednesday, hitting $73.08. 9,168,543 shares of the company traded hands, compared to its average volume of 4,058,806. The firm's fifty day moving average is $73.50 and its 200-day moving average is $76.92. GE HealthCare Technologies has a 12-month low of $57.65 and a 12-month high of $94.80. The firm has a market capitalization of $33.46 billion, a P/E ratio of 15.39, a P/E/G ratio of 2.62 and a beta of 1.14. The company has a current ratio of 0.98, a quick ratio of 0.76 and a debt-to-equity ratio of 0.73.
Read Our Latest Research Report on GEHC
Sarepta Therapeutics (SRPT)
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
SRPT traded up $2.14 during trading hours on Wednesday, reaching $17.97. 28,429,441 shares of the company's stock traded hands, compared to its average volume of 5,609,552. The firm has a 50-day moving average price of $25.16 and a 200 day moving average price of $62.52. The firm has a market capitalization of $1.77 billion, a PE ratio of -6.73 and a beta of 0.45. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $145.00.
Read Our Latest Research Report on SRPT
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Thermo Fisher Scientific stock traded up $0.17 during mid-day trading on Wednesday, hitting $482.33. The company's stock had a trading volume of 1,044,224 shares, compared to its average volume of 2,512,563. The company has a 50 day moving average of $416.56 and a 200-day moving average of $468.86. The stock has a market cap of $182.08 billion, a PE ratio of 27.87, a P/E/G ratio of 2.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific has a one year low of $385.46 and a one year high of $627.88.
Read Our Latest Research Report on TMO
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK traded up $0.26 during trading on Wednesday, hitting $82.89. 5,946,123 shares of the stock were exchanged, compared to its average volume of 15,834,751. The firm has a 50 day simple moving average of $80.27 and a 200 day simple moving average of $84.98. The firm has a market cap of $208.15 billion, a price-to-earnings ratio of 12.03, a P/E/G ratio of 0.86 and a beta of 0.39. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $120.30. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.16 and a current ratio of 1.41.
Read Our Latest Research Report on MRK
AstraZeneca (AZN)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
AZN traded up $2.54 during trading on Wednesday, hitting $76.52. 5,854,843 shares of the stock were exchanged, compared to its average volume of 5,338,532. The firm has a 50 day simple moving average of $71.28 and a 200 day simple moving average of $71.22. The firm has a market cap of $237.31 billion, a price-to-earnings ratio of 30.69, a P/E/G ratio of 1.32 and a beta of 0.37. AstraZeneca has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.70 and a current ratio of 0.90.
Read Our Latest Research Report on AZN
Featured Stories
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
